国家: 美国
语言: 英文
来源: NLM (National Library of Medicine)
FENOFIBRATE (UNII: U202363UOS) (FENOFIBRIC ACID - UNII:BGF9MN2HU1)
Teva Pharmaceuticals USA Inc
FENOFIBRATE
FENOFIBRATE 145 mg
ORAL
PRESCRIPTION DRUG
Fenofibrate tablets for oral use are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), Triglycerides and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia. Fenofibrate tablets for oral use are also indicated as adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied. Fenofibrate at a dose equivalent to 145 mg of Fenofibrate tablets for oral use was not shown to reduce coronary heart disease morbidity and mortality in a large, randomized con
Fenofibrate tablets for oral use are available in two strengths: 48 mg Yellow tablets, imprinted with the code identification letters “FI”, available in bottles of 90 (NDC 0093-7755-98). Yellow tablets, imprinted with the “a” logo and code identification letters “FI”, available in bottles of 90 (NDC 0093-2061-98). 145 mg White tablets, imprinted with the code identification letters “FO”, available in bottles of 90 (NDC 0093-7756-98). White tablets, imprinted with the “a” logo and code identification letters “FO”, available in bottles of 90 (NDC 0093-2060-98). Storage Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). [See USP Controlled Room Temperature]. Keep out of the reach of children. Protect from moisture.
New Drug Application Authorized Generic
FENOFIBRATE- FENOFIBRATE TABLET TEVA PHARMACEUTICALS USA INC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE FENOFIBRATE TABLETS FOR ORAL USE SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR FENOFIBRATE TABLETS FOR ORAL USE. FENOFIBRATE TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 1993 RECENT MAJOR CHANGES Warnings and Precautions, Hypersensitivity Reactions (5.9) 05/2018 INDICATIONS AND USAGE Fenofibrate tablets for oral use are a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet: To reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (1.1). For treatment of adult patients with severe hypertriglyceridemia (1.2). Limitations of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus (5.1). DOSAGE AND ADMINISTRATION Primary hypercholesterolemia or mixed dyslipidemia: Initial dose of 145 mg once daily (2.2). Severe hypertriglyceridemia: Initial dose of 48 to 145 mg once daily. Maximum dose is 145 mg (2.3). Renally impaired patients: Initial dose of 48 mg once daily (2.4). Geriatric patients: Select the dose on the basis of renal function (2.5). Maybe taken without regard to meals (2.1). DOSAGE FORMS AND STRENGTHS Oral Tablets: 48 mg and 145 mg (3). CONTRAINDICATIONS Severe renal dysfunction, including dialysis patients (4, 8.6, 12.3). Active liver disease (4, 5.3). Gallbladder disease (4, 5.5). Known hypersensitivity to fenofibrate (4). Nursing mothers (4, 8.2). WARNINGS AND PRECAUTIONS Myopathy and rhabdomyolysis have been reported in patients taking fenofibrate. Risks are increased during co- administration with a statin (with a significantly higher rate observed for gemfibrozil), particularly in elderly patients and patients with diabetes, renal failure, or hypothyroidism (5.2). Fenofibrate tablets for oral use can increase seru 阅读完整的文件